Damaged elastin-targeted calcification delivery platform
preclinicalDeliver therapies directly to sites of vascular calcification without invasive surgery or lifelong systemic drug exposure, with potential use across cardiovascular and age-related conditions.
Targeting platform based on an antibody specific for damaged elastin fibers, used to direct therapeutic nanoparticles to calcified tissue.
Platform demonstrated in preclinical work using elastin antibody-conjugated nanoparticles to target calcified tissue and deliver EDTA in rat and ex vivo human artery models.
Site material states the platform delivers therapy directly to calcification sites and may address multiple cardiovascular and age-related conditions. The supplied publication supports targeting of elastin antibody-conjugated nanoparticles to calcification areas and therapeutic reversal of calcification when loaded with EDTA.